Company / Capital Expenditures
Vaxcyte, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$13.7M
FY2025
5-year range
$5.8M / $22.4M
FY2021-FY2025
Trend
-38.9%
vs FY2024
Sector context
#52 of 194
Health Care
What the data says
At $14M, Vaxcyte, Inc.'s capital expenditures ranks #52 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 8 years, ranging from $1M in FY2020 to $22M in FY2024.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +64.0%.
Declined from $16M to $14M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +32.9%
- 5-Year CAGR
- +64.0%
- 10-Year CAGR
- -
Sector benchmark
#52 of 194 in Health CareTop 27% of 194This company $13.7M Sector average $117.5M
▼
-88.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +64.0%, indicating consistent growth.
- In FY2025, capital expenditures decreased 38.9% year-over-year.
- Ranks #52 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.7M | -38.9% |
| FY2024 | $22.4M | +39.6% |
| FY2023 | $16.1M | +175.0% |
| FY2022 | $5.8M | -10.9% |
| FY2021 | $6.6M | +467.5% |
| FY2020 | $1.2M | -3.3% |
| FY2019 | $1.2M | -32.6% |
| FY2018 | $1.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026